Incidence and Risk Factors of Postoperative Sarcopenia in Elderly Patients Following Hip Fracture Surgery: A Retrospective Cohort Analysis - Top-Institutions - MDSpire

Incidence and Risk Factors of Postoperative Sarcopenia in Elderly Patients Following Hip Fracture Surgery: A Retrospective Cohort Analysis

  • By

  • Hang Yin

  • Chao Qin

  • Qi Tang

  • Guoli Wu

  • He Diao

  • April 22, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Geriatrics
    • Orthopedics
    • Rehabilitation Medicine
    • Nutrition

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Geriatrics
    • Orthopedics
    • Epidemiology
    • Rehabilitation

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Geriatrics
    • Orthopedics
    • Rehabilitation Medicine
    • Nutrition Science

  • #4

    Hospital for Special Surgery (HSS)
    Hospital for Special Surgery (HSS)

    New York, NY

    Key Differentiators

    • Orthopedics
    • Geriatrics
    • Rehabilitation

  • #5

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Geriatrics
    • Orthopedics
    • Rehabilitation Medicine

Original Source(s)

Incidence and Risk Factors of Postoperative Sarcopenia in Elderly Patients Following Hip Fracture Surgery: A Retrospective Cohort Analysis

  • by Hang Yin, Chao Qin, Qi Tang, Guoli Wu, He Diao

  • April 22, 2026

Related Content

Association of Sleep Quality and Sleep Duration with Anxiety Symptoms in Older Adults: A Systematic Review and Meta-Analysis

Exploring the Relationship Between Sleep Duration, Depression, and Postoperative Delirium: A Mediation Study

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.